Navigation Links
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Date:11/19/2007

nual and interim reports filed with the Frankfurt Stock Exchange. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing, progress and results of the clinical development, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals Inc.

References

(1) World Health Organization. Hepatitis B. Available at:

http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/.

Accessed April 10, 2007

(2) Penn State Milton S. Hershey Medical Center College of Medicine.

Malignant Hepatoma. Available at:

http://www.hmc.psu.edu/healthinfo/m/malignanthepatoma.htm. Accessed

April 10, 2007.

(3) International
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support ... heart failure, today announced that it expects revenues ... approximately $53 million, bringing expected full-year 2013 revenues ... revenue growth of 87% for 2013 above 2012 ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... event for buyers and sellers of high-value chemistry, will ... conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 attendees ... will take part in the conference, which includes on-site ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... As part of a three-year global initiative to identify ... problems around the world, Boehringer Ingelheim and Ashoka,s Changemakers® ... Health: Achieving Individual, Family, and Community Well-Being ... the most innovative models and solutions that are transforming ...
... England, July 6, 2011 , Vantia ... targeting large areas of,unmet medical need, today announces it ... series B round. The round was co-led by Novo ... Partners, all,existing investors in Vantia. The funds have been ...
Cached Medicine Technology:Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition 2Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition 3Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds 2Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Quality Act, Would Save Thousands of Lives,Billions of Dollars, ... joined forces Wednesday, April 2, 2008, with U.S.,Senate health ... Health Care,Quality Act," a measure to bring the power ... view the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/brt/32565/ , ...
... Top of Medical ... Coverage, CHARLOTTE, N.C., April ... care and insurance benefits should be,a much easier task for the bank,s associates ... costs, and give,associates more flexibility in the way they choose and pay for ...
... Opportunity to Emerging Hip-Hop ... Talent, NEW ... TAG brand announce the formation of a new,hip-hop record label, TAG Records. The ... president of the New York-based,venture. As president, Dupri will set the creative vision ...
... ISTA,Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... United States Attorney,s Office in Buffalo requesting the,production ... to Xibrom(TM) (bromfenac sodium ophthalmic solution),0.09%., It ... applicable U.S. and,foreign laws, rules and regulations of ...
... Like horses running down the long stretch of a ... neck-and-neck when it comes to preventing stroke among people with ... years, patients who had a minimally-invasive procedure were just as ... die, as those who had open-neck surgery. , The findings ...
... Efforts to Safeguard Sight, Promote Healthy Vision ... for Children and Expand Access to Care, ... recognized for providing important leadership on health care,policy issues by ... 34,000 member American Optometric Association (AOA).,Optometrists in West Virginia and ...
Cached Medicine News:Health News:Video: Senators and CEOs Urge Passage of Health IT Bill Now 2Health News:Video: Senators and CEOs Urge Passage of Health IT Bill Now 3Health News:Bank of America Launches Innovative Approach to Managing Health Care 2Health News:Bank of America Launches Innovative Approach to Managing Health Care 3Health News:Bank of America Launches Innovative Approach to Managing Health Care 4Health News:Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays 2Health News:Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays 3Health News:ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM) 2Health News:ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM) 3Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 2Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 3Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 4Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2
... Iodine 'Prep' solutions are ... mucous membrane preparation prior ... Povidone Iodine 'Scrub' solutions ... surfactants. Each is effective ...
Triad Plus PVP-I Scrub Solution has broad-spectrum germicidal action.This special formula is designed to help break down body oils and yet limit the bubbles the surfactants allowing easy removal and ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... are designed for individual application and are ... in nursing homes, home healthcare settings, blood ... hospital departments. This unit dose pouch contains ... germicidal and cleansing agent. Hydrogen Peroxide's chief ...
Medicine Products: